-+ 0.00%
-+ 0.00%
-+ 0.00%

A Look At Tilray Brands (TLRY) Valuation After Its New Dry January Alternative Beverages Launch

Simply Wall St·01/07/2026 02:18:54
语音播报

Tilray Brands (TLRY) is drawing fresh attention after rolling out a Dry January Collection built around cannabis infused and non alcoholic drinks, targeting the growing sober curious trend and functional beverage demand.

See our latest analysis for Tilray Brands.

Tlray Brands shares have been volatile, with a 30 day share price return of 25.99% but a 90 day share price return decline of 46.16%. The 1 year total shareholder return is down 36.14%, suggesting recent Dry January excitement is building from a weak longer term base at a current share price of $9.26.

If this kind of product driven story interests you, it could be a good moment to widen your watchlist and check out healthcare stocks as potential alternatives.

With Tilray posting a recent 30 day gain alongside weak 1 year returns, and trading at a discount to the current analyst price target, the key question is whether this reset creates a potential buying window or if the market is already incorporating expectations for future growth.

Most Popular Narrative Narrative: 42.7% Undervalued

Tilray Brands' most followed narrative puts fair value at US$16.17 per share versus the last close of US$9.26. This frames a sizeable valuation gap for investors to assess.

Tilray's international cannabis business is achieving rapid organic growth, with European cannabis revenue up 112% YoY (excluding Australia) and significant share gains in Germany due to regulatory tailwinds, broader medical adoption, and expanding legalization, which together support a long runway for top-line revenue acceleration as global cannabis markets open.

Read the complete narrative.

Want to see what justifies that kind of gap between price and fair value? The narrative leans heavily on measured revenue growth, margin repair, and a future earnings multiple that looks very different from today.

Result: Fair Value of $16.17 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the story could change quickly if long running net losses and negative free cash flow continue, or if regulatory setbacks slow international cannabis market access.

Find out about the key risks to this Tilray Brands narrative.

Build Your Own Tilray Brands Narrative

If you think the current story misses something, or you would rather test the assumptions yourself, you can build a custom Tilray view in minutes, starting with Do it your way.

A great starting point for your Tilray Brands research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.

Ready to hunt for more opportunities?

If Tilray has your attention, do not stop here. Broaden your watchlist now so you are not looking back later wishing you had checked a few more ideas.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.